Thanks @NASDAQ for helping us celebrate our $170M Series D to accelerate clinical development for obesity therapeutics and advance our pipeline. Thrilled to partner with top-tier investors & pharma—and it's great to be up on the big screen! 👉🏼businesswire.com/news/home/2024…

NLRP3 is implicated in many age-related diseases. Our new paper describes how BioAge discovered novel NLRP3 inhibitors, which we're developing—including the Ph1-ready CNS-penetrant oral drug BGE-100—for inflammatory, metabolic, & age-related indications. sciencedirect.com/science/articl…

Interesting target and approach Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) Insilico Medicine nature.com/articles/s4158…

Shouldn’t aging be part of drug discovery for diseases of aging? gordian.bio/blog/introduci… Gordian exists to move therapeutic testing from plastic wells and young mice into a living environment with all the complexity present in patients with age-related disease. We’re now

Introducing Cradle, co-founded with Hunter C Davis. We're building reversible cryo technologies. Think the hibernation pods you see in space movies for long-term travel - we want to build that. We’ve raised $48M, built a world-class team of scientists and engineers,

Excited to share that we've officially started our Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity. Congratulations to the team at BioAge and our collaborators at Lilly Chorus!

Anyone who cares about longevity science should read the @A4Li proposal "A New National Institute for Longevity and Aging Research (NILAR)" . It's a start toward much needed reform at NIH. I've signed the petition and encourage you to do so as well: a4li.org/support-nilar/

BioAge is pleased to announce the appointment of Jean-Pierre Garnier, PhD, as Chair of our Board of Directors. Dr. Garnier, who was CEO of GSK and board chair of multiple biopharma companies, brings unparalleled industry leadership to our Board. businesswire.com/news/home/2024…

BioAge is now a public company! I'm incredibly proud of our team and grateful to our partners and investors who made this possible. By targeting the biology of aging, we're developing therapies to tackle metabolic diseases and change lives. Excited for what's ahead!

E11 Bio is excited to share a major step towards brain mapping at 100x lower cost, making whole-brain connectomics at human & mouse scale feasible (🧠→🔬→💻). Critical for curing brain disorders, building human-like AI systems, and even simulating human brains. 1/N 🧵

I’m pleased to share that Novartis has entered a collaboration with BioAge aimed at discovering novel targets for potential therapies for age-related diseases. We look forward to the groundbreaking discoveries that this collaboration could bring. ir.bioagelabs.com/news-releases/…

BioAge is excited to announce a multi-year research collaboration with Novartis focused on discovering novel therapeutic targets for age-related diseases. By exploring the molecular mechanisms at the intersection of aging biology and exercise, we aim to accelerate the

What if we had therapies to extend healthspan and prevent the onset of age related diseases? I’m excited to announce my first ARPA-H program, PROSPR. The goal is to develop validated surrogate biomarkers, new clinical endpoints and therapies to collectively extend healthspan

In Boston, BioAge visited Novartis to kick off our multi-year collaboration to discover novel targets for therapies that address age-related diseases! Our Aging and Physical Exercise Target Discovery (APEx) data science team met with Sophie Lemire-Brachat, Head of

Loyal’s drug for senior dog lifespan extension drug LOY-002 has completed its FDA efficacy package (RXE) We are on track to hopefully bring the first longevity drug to market *this year* Thanks Lisa Bonos + The Washington Post for the exclusive

We’re happy to share that BioAge’s BGE-102—a potent, brain-penetrant, once-daily oral NLRP3 inhibitor—has completed IND-enabling studies and is advancing toward the clinic, with Phase 1 single-ascending-dose (SAD) data expected by year-end. Read the release:

We’re pleased to announce that BioAge is expanding our preclinical APJ agonist pipeline with highly potent oral small-molecule and injectable candidates designed to address key unmet needs in obesity treatment. APJ agonists are designed to mimic the effects of apelin, an

BioAge is excited to kick off a new initiative with Norway’s HUNT Biobank - one of Europe's most comprehensive population health studies - to map how molecular changes across decades shape healthy aging. globenewswire.com/news-release/2… Through our collaboration with Norwegian

Excited to share our new preprint on our research providing detailed structural insights into BioAge’s novel class of brain-penetrant NLRP3 inhibitors, targeting a core driver of metabolic aging. In this study, we identified a new binding pocket on NLRP3 and demonstrated how it

NEW: No technology currently exists to repair damaged brain tissue and fully restore lost function. FRONT aims to enable millions with what is considered permanent brain damage to regain lost functions, including motor control, vision, and speech. arpa-h.gov/news-and-event…